Privo Technologies Secures New Patents in Three Nations
The clinical-stage cancer therapy developer reports newly issued patents in the United States, Canada and India, with more pending abroad.
Updated on Nov. 2, 2026 in Cancer
Privo Technologies, a clinical-stage biopharmaceutical company developing localized cancer therapies, announced newly issued patents in the United States, Canada and India. The company also advanced toward patent grants in Japan, Australia and Europe.
Why it matters
Patent protection can shape how long a developer keeps exclusive rights to its localized cancer delivery technologies as it advances clinical programs. Coverage across several major markets indicates the company is seeking protection beyond its home jurisdiction.
The company reports 13 issued or allowed patents as of October 13, 2026, including three issued U.S. patents covering the rapid-release patch technology behind PRV211. Grant timelines for the pending applications in Japan, Australia and Europe were not disclosed.
The players
Privo Technologies
Privo Technologies is a clinical-stage biopharmaceutical company based in Boston that develops localized cancer therapies using topical, intraoperative and intratumoral delivery approaches.
The details
Privo's pipeline includes the PRV111 topical patch, the PRV211 intraoperative patch and the PRV131 intratumoral injectable programs, all designed to deliver high anticancer doses directly to targeted tissue while limiting systemic exposure. The company says its intellectual property combines patents on compositions, delivery systems and methods with proprietary manufacturing and formulation know-how.
Timeline
October 13, 2026: Privo's portfolio reached 13 issued or allowed patents.
November 2, 2026: Privo announced the new patent issuances and advances.
Big Picture
Localized delivery platforms such as Privo's intraoperative patch aim to concentrate cancer drugs in target tissue while limiting whole-body exposure. Securing patents across the United States, Canada, India and pending markets helps a developer defend that approach as it moves through clinical development.
Localized delivery therapies are investigational and not yet available as routine treatment, so patients should continue to follow guidance from their oncology team. Any future approval would depend on clinical trial results and regulatory review in each market.
The takeaway
Patent grants signal legal protection for a technology, not clinical proof that it works. Readers should watch for trial results before drawing conclusions about patient benefit.
Further reading
For more on the disease and treatment landscape behind this news, see the Cancer section.
Source note: This article includes information reported by Firstwordpharma.
